GLP-1 Agonists: Practical Strategies for Clinicians to Manage the Adverse Effects

GLP-1 receptor agonists, widely used for type 2 diabetes and weight management, often cause gastrointestinal side effects that clinicians must address proactively. Here are some practical strategies to clinicians and primary care physicians for handling these issues to optimise patient outcomes.

Common GI Side Effects

Nausea, vomiting, diarrhea, constipation, abdominal pain, distension, dyspepsia, flatulence, and belching hit up to 50% of users during dose escalation. These dose-dependent symptoms are usually mild, fading in weeks, but demand caution in severe GI conditions like IBD or gastroparesis. Slower titration or drug holidays help persistent cases.

Practical Mitigation Strategies

Start low and increase it gradually to minimise GI upset—titrate semaglutide from 0.25 mg weekly, increasing gradually every 4 weeks. This approach reduces peak drug levels that provoke symptoms. Counsel patients on habits: eat slowly, only when hungry, stop when full; opt for small, frequent low-fat meals over large traditional ones; skip late-night eating. Recommend low-fat, non-spicy diets, 2-2.5L daily clear fluids, and hydration via water-rich foods. For severe symptoms, short-term aids like PPIs, antiemetics, laxatives, or antidiarrheals bridge tolerance.

Management Techniques

For persistent nausea, antiemetics like ondansetron or prochlorperazine provide quick relief without interacting adversely with GLP-1s. Prokinetics such as metoclopramide can aid gastric emptying in cases of gastroparesis-like symptoms. Constipation responds to osmotic laxatives like polyethylene glycol, while loperamide helps control diarrhea short-term; probiotics may support gut flora balance long-term.

Serious Adverse Effects

UK’s MHRA flags acute pancreatitis risks, including rare necrotising/fatal cases: 1296 reports (19 fatal) from 2007-2025 amid 25 million packs dispensed recently. Stop therapy for severe back-radiating pain with nausea; avoid in pancreatitis history. Hair loss (telogen effluvium) affects 1 in 10 due to rapid weight loss but reverses in 3-6 months—reassure patients.

Vision and Medication Warnings

Semaglutide links to rare nonarteritic anterior ischemic optic neuropathy (NAION), causing sudden painless vision loss (blurring/cloudiness) from optic nerve hypoperfusion; just 3 UK cases since 2018 on 10 million packs. Urge immediate ophthalmology referral and discontinuation for vision changes; diabetics already face higher risk with smoking, hypertension, dyslipidemia. GLP-1s delay gastric emptying but rarely alter most oral meds—monitor narrow-index drugs like digoxin or warfarin.

Benefits vs. Long-Term Affordability

The benefits of GLP-1s far outweigh the adverse effects for the majority of people living with type 2 diabetes or obesity. Cardiovascular gains and sustained weight loss justify use for most, yet affordability looms: high costs strain patients, taxpayers, and governments, especially if surgery-eligible patients stall bariatric options.

Long-Term Considerations

Monitor for thyroid C-cell tumors in high-risk patients (family history), though human data remains reassuring. Bone health and muscle loss with rapid weight reduction warrant DEXA scans and protein-rich diets. Emerging data supports GLP-1s’ cardiovascular benefits, outweighing risks for most, but shared decision-making is key.

Surgery Delay Dilemma

For bariatric candidates, do GLP-1s deliver comparable outcomes without knives, or merely postpone surgery while inflating expenses? Early data shows impressive weight loss (15-20% body weight), but durability wanes off-drug; surgery offers more permanent results at potentially lower lifetime cost. Clinicians must weigh: short-term tolerance vs. lifelong adherence, surgery risks vs. med side effects, and systemic burdens.

Patient-Centered Guidance

Educate on transient issues, track symptoms, and personalise plans. Most tolerate long-term with tweaks, achieving glycemic control and heart protection. Yet, for surgery candidates, integrate GLP-1s as bridges, not barriers—monitor progress rigorously to avoid cost traps.

Reference : https://www.medscape.com/viewarticle/1003255#vp_1